Top Stories

Two new PCSK9 monoclonal antibodies have been given a nod of approval to the Food and Drug Administration (FDA). The FDA Endocrinologic and Metabolic Drugs Advisory Committee reviewed the evidence on the new class of cholesterol-lowering drugs and recommended that the FDA should approve the new class of LDL-lowering drugs.

This is great news, especially for high risk patients and for Familial Hypercholesterolemia (FH) patients who are not at their LDL-C and non-HDL-C goals on optimal therapy. The NLA is excited about this decision by the FDA advisory committee.

The National Lipid Association (NLA) was surveyed this year by the Accreditation Council for Continuing Medical Education (ACCME) and awarded Accreditation with Commendation for the next six years as a provider of continuing medical education for physicians. The NLA’s new accreditation term expires November 30, 2020.

Adding ezetimibe to statin therapy further lowered cholesterol levels and resulted in fewer cardiovascular events in patients following heart attack
 

More than a decade ago, researchers from Brigham and Women’s Hospital (BWH) demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.